Pathogens Leading to Central Line–Associated Bloodstream Infections Present on Admissiona
| Organism . | CLABSI-POA Cases, No. (%) (N = 461) . |
|---|---|
| Low-level category | |
| Enterobacterales | 177 (29.2) |
| Coagulase-negative staphylococci | 105 (17.3) |
| Staphylococcus aureus | 94 (15.5) |
| Streptococcus | 78 (12.9) |
| Non-Enterobacteriaceae GNR | 63 (10.4) |
| Yeast | 51 (8.4) |
| Anaerobes | 18 (3.0) |
| Aerobic GPR | 8 (1.3) |
| Actinomyces | 6 (1.0) |
| Nonyeast fungus | 3 (0.5) |
| Mycobacterium | 2 (0.3) |
| Other GPC | 1 (0.2) |
| Type of MDRO | |
| MRSA | 36 (69.2) |
| ESBL | 7 (13.5) |
| VRE | 7 (13.5) |
| Candida auris | 1 (1.9) |
| VISA | 1 (1.9) |
| >1 MRDO | 1 (1.9) |
| Total MDROs | 52 (11.3) |
| Organism . | CLABSI-POA Cases, No. (%) (N = 461) . |
|---|---|
| Low-level category | |
| Enterobacterales | 177 (29.2) |
| Coagulase-negative staphylococci | 105 (17.3) |
| Staphylococcus aureus | 94 (15.5) |
| Streptococcus | 78 (12.9) |
| Non-Enterobacteriaceae GNR | 63 (10.4) |
| Yeast | 51 (8.4) |
| Anaerobes | 18 (3.0) |
| Aerobic GPR | 8 (1.3) |
| Actinomyces | 6 (1.0) |
| Nonyeast fungus | 3 (0.5) |
| Mycobacterium | 2 (0.3) |
| Other GPC | 1 (0.2) |
| Type of MDRO | |
| MRSA | 36 (69.2) |
| ESBL | 7 (13.5) |
| VRE | 7 (13.5) |
| Candida auris | 1 (1.9) |
| VISA | 1 (1.9) |
| >1 MRDO | 1 (1.9) |
| Total MDROs | 52 (11.3) |
Abbreviations, CLABSI-POA, central line–associated bloodstream infection present on admission; ESBL, extended spectrum β-lactamase; GNR, gram-negative rod; GPC, gram-positive cocci; GPR, gram-positive rod; MDRO, multidrug-resistant organisms; MRSA, methicillin-resistant Staphylococcus aureus; VISA, vancomycin-intermediate/resistant S. aureus; VRE, vancomycin-resistant enterococci.
aData were displayed by ranking frequencies among all study patients.
Pathogens Leading to Central Line–Associated Bloodstream Infections Present on Admissiona
| Organism . | CLABSI-POA Cases, No. (%) (N = 461) . |
|---|---|
| Low-level category | |
| Enterobacterales | 177 (29.2) |
| Coagulase-negative staphylococci | 105 (17.3) |
| Staphylococcus aureus | 94 (15.5) |
| Streptococcus | 78 (12.9) |
| Non-Enterobacteriaceae GNR | 63 (10.4) |
| Yeast | 51 (8.4) |
| Anaerobes | 18 (3.0) |
| Aerobic GPR | 8 (1.3) |
| Actinomyces | 6 (1.0) |
| Nonyeast fungus | 3 (0.5) |
| Mycobacterium | 2 (0.3) |
| Other GPC | 1 (0.2) |
| Type of MDRO | |
| MRSA | 36 (69.2) |
| ESBL | 7 (13.5) |
| VRE | 7 (13.5) |
| Candida auris | 1 (1.9) |
| VISA | 1 (1.9) |
| >1 MRDO | 1 (1.9) |
| Total MDROs | 52 (11.3) |
| Organism . | CLABSI-POA Cases, No. (%) (N = 461) . |
|---|---|
| Low-level category | |
| Enterobacterales | 177 (29.2) |
| Coagulase-negative staphylococci | 105 (17.3) |
| Staphylococcus aureus | 94 (15.5) |
| Streptococcus | 78 (12.9) |
| Non-Enterobacteriaceae GNR | 63 (10.4) |
| Yeast | 51 (8.4) |
| Anaerobes | 18 (3.0) |
| Aerobic GPR | 8 (1.3) |
| Actinomyces | 6 (1.0) |
| Nonyeast fungus | 3 (0.5) |
| Mycobacterium | 2 (0.3) |
| Other GPC | 1 (0.2) |
| Type of MDRO | |
| MRSA | 36 (69.2) |
| ESBL | 7 (13.5) |
| VRE | 7 (13.5) |
| Candida auris | 1 (1.9) |
| VISA | 1 (1.9) |
| >1 MRDO | 1 (1.9) |
| Total MDROs | 52 (11.3) |
Abbreviations, CLABSI-POA, central line–associated bloodstream infection present on admission; ESBL, extended spectrum β-lactamase; GNR, gram-negative rod; GPC, gram-positive cocci; GPR, gram-positive rod; MDRO, multidrug-resistant organisms; MRSA, methicillin-resistant Staphylococcus aureus; VISA, vancomycin-intermediate/resistant S. aureus; VRE, vancomycin-resistant enterococci.
aData were displayed by ranking frequencies among all study patients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
